Updated: FDA explains why it won't pull Jazz's accelerated approval despite a failed confirmatory trial
When does a failed confirmatory trial evaluating overall survival not amount to a request from FDA to pull an accelerated approval for a cancer drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
